Business
N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across
About this update from Nexentis Technologies Inc.
[{"type":"text","content":"New identity reflects Company’s evolution into an innovative data driven biotech company leveraging MITOLINE™ and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve Yarak, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today announced a comprehensive corporate rebranding to Nexentis Technologies Inc. (“Nexentis”) and change in the trading symbol of the Company to “NXTS” on the Nasdaq Capital Market. The name change and the symbol change will take effect on the Nasdaq Capital Market on February 26, 2026. The new name and brand are designed to reflect the Company’s transformation into an innovative AI and data‑driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. At the core of this rebranding is the integration and scaling of MitoCareX Bio Ltd. (“MitoCareX”), now a wholly‑owned subsidiary of the Company, which brings a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE™ algorithm and structure‑guided virtual screening workflows. Nexentis intends to harness this platform to build a diversified pipeline of first‑in‑class small‑molecule programs, while continuing to selectively manage its RTB solar energy investments as a non‑core, value‑optimizing asset base. The rebranding follows a strategic process and a series of recent milestones that have repositioned the Company: Closing of MitoCareX acquisition and strategic pivot to biotech: On October 20, 2025, N2OFF completed the acquisition of MitoCareX, a biotechnology company focused on drug discovery for resistant cancers and inflammatory metabolic disease indications through targeting the mitochondrial SLC25 protein family, with MitoCareX becoming a wholly‑owned subsidiary. The transaction marked a deliberate expansion from cleantech into biotechnology and established the foundation for the Company’s drug discovery and development‑focused strategy.Validation of the MITOLINE™ discovery platform: MitoCareX has generated multiple rounds of in vitro data using its MITOLINE™‑powered discovery engine, including earlier studies demonstrating anti‑tumor activity and ta...